Intellia Therapeutics, Inc. (NTLA) Receives Consensus Rating of “Buy” from Analysts
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned an average recommendation of “Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $27.17.
Several research analysts recently issued reports on NTLA shares. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of Intellia Therapeutics in a research report on Monday, May 15th. Credit Suisse Group set a $24.00 target price on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. TheStreet raised Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Finally, Cann reaffirmed a “market perform” rating on shares of Intellia Therapeutics in a research report on Monday, July 17th.
Shares of Intellia Therapeutics (NTLA) opened at 22.20 on Friday. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $22.49. The company has a 50-day moving average price of $17.76 and a 200-day moving average price of $15.09. The company’s market cap is $801.69 million.
Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. The company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The firm’s quarterly revenue was up 40.5% on a year-over-year basis. On average, analysts predict that Intellia Therapeutics will post ($1.78) earnings per share for the current year.
In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of Intellia Therapeutics stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.80% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth about $167,000. California State Teachers Retirement System raised its position in shares of Intellia Therapeutics by 79.0% in the 2nd quarter. California State Teachers Retirement System now owns 25,143 shares of the company’s stock worth $402,000 after acquiring an additional 11,100 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Intellia Therapeutics by 451.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock worth $212,000 after acquiring an additional 10,825 shares in the last quarter. State Street Corp raised its position in shares of Intellia Therapeutics by 52.0% in the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after acquiring an additional 56,363 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Intellia Therapeutics by 19.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 48,566 shares of the company’s stock worth $777,000 after acquiring an additional 7,866 shares in the last quarter. 46.52% of the stock is owned by hedge funds and other institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.